Table of Contents Author Guidelines Submit a Manuscript
International Journal of Surgical Oncology
Volume 2017, Article ID 7161437, 7 pages
Research Article

Treatment Outcome of Carcinoma Vulva Ten-Year Experience from a Tertiary Cancer Centre in South India

1Department of Surgical Oncology, Tamil Nadu Multi-Super Specialty Hospital, Chennai, Tamil Nadu, India
2Department of Surgical Oncology, Thoothukudi Medical College, Thoothukudi, Tamil Nadu, India
3Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, Preston, UK
4Department of Surgical Oncology, Coimbatore Medical College & Hospital, Coimbatore, Tamil Nadu, India
5Department of Surgical Oncology, Government Royapettah Hospital and Kilpauk Medical College, Chennai, India

Correspondence should be addressed to Sakthiushadevi Jeevarajan; moc.liamg@ivedahsuihtkas

Received 3 September 2017; Accepted 15 October 2017; Published 14 December 2017

Academic Editor: C. H. Yip

Copyright © 2017 Sakthiushadevi Jeevarajan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Carcinoma vulva is a rare disease accounting for 1.3% of all gynaecological malignancies. The present study is a 10-year retrospective review of our experience of the surgical options, morbidity, failure pattern, and survival for invasive carcinoma vulva. Materials and Methods. Retrospective analysis of case records of 39 patients who underwent surgery for invasive vulval cancer between 2004 and 2013 in the Department of Surgical Oncology at the Government Royapettah Hospital, Chennai. Results. The median age was 55 years. Radical vulvectomy was the preferred surgery. 31 patients underwent lymphadenectomy. Seroma formation and groin skin necrosis were the most common postoperative complications. With a median follow-up of 32 months, 8 patients (20.5%) developed recurrence (systemic = 1, regional = 4, and local = 3). The estimated 5-year disease-free survival (DFS) was 65.4% and the overall survival (OS) was 85.1%. On univariate analysis, stage and lymph node involvement significantly affected OS. Nodal involvement with extracapsular spread (ECS) significantly affected both DFS and OS. Conclusion. The treatment of carcinoma vulva should be individualized with multidisciplinary cooperation. The paucity of data, especially from India, necessitates the need for more studies, preferably multicentric, keeping in mind the low prevalence.